Thursday, July 19, 2018
 
 
Company News: Page (1) of 1 - 04/03/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
genedrive to premier its GenedriveŽ Hepatitis C test in Asia Pacific

(April 03, 2018)

3 April 2018

genedrive plc ("genedrive" or the "Company")

  

GenedriveŽ HCV ID Kit to be presented at MEDLAB Asia Pacific Exhibition & Congress



genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces it will premiere its GenedriveŽ HCV ID Kit in the Asia Pacific region at the MEDLAB Asia Pacific Exhibition & Congress in Singapore on 2-4 April 2018.

GenedriveŽ HCV ID Kit is a qualitative HCV assay, providing results within 90 minutes and is designed for use in a decentralised testing environment. It is performed on the company's portable molecular diagnostics platform, GenedriveŽ, and was created to support the roll-out of direct-acting antivirals in low and middle income countries.

genedrive recently announced first commercial sales of instruments and assays to Sysmex Europe GmbH to cover Europe, Middle East and Africa and Sysmex Asia Pacific Pte Ltd for the Asia Pacific region, excluding India. In addition, the GenedriveŽ HCV ID Kit's first external validation study was successfully conducted in South Africa with results announced in early January 2018 showing 100% specificity and sensitivity in independent use, confirming that our good clinical validation performance can be translated into real-world settings.

MEDLAB is a significant and highly attended event in the Asia Pacific region for leading companies to showcase their technologies and innovations in the field of laboratory diagnostics. With over 4,000 delegates from around the world, the congress features products in many areas including point of need and infectious diseases.

The GenedriveŽ HCV-ID Kit will be presented and demonstrated together with Sysmex Asia Pacific at booth M19 at the Suntec Singapore Convention & Exhibition Centre.

-  Ends  -

For further details please contact:
genedrive plc
David Budd: CEO                                                                                                              +44 (0)161 989 0245
Matthew Fowler: CFO

Peel Hunt LLP
James Steel                                                                                                                      +44 (0)207 418 8900
Oliver Jackson

Consilium Strategic Communications
Chris Gardner                                                                                                                    +44 (0)203 709 5700
Matthew Neal
Laura Thornton
[email protected] 

Notes to Editors

About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The GenedriveŽ HCV ID Kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the GenedriveŽ platform in the EMEA  and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the GenedriveŽ HCV ID Kit and GenedriveŽ platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com

About Hepatitis C
Hepatitis C (HCV) is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150-200 million people, or approximately 3% of the world's population, are living with chronic HCV, and more than 350,000 people die yearly from HCV related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90% however access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate HCV.


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research
  • Wireless Health Market To Witness Enhanced Growth Owing To Rising Application of Wireless Health Devices And Growing Patient-Centric Methodology Till 2025 | Million Insights
  • Robotics Prosthetics Market Exclusive Analysis by MRFR | Industry Growing with 9.5% CAGR up to 2027 | The Demand for Robotic Prosthetic is Found to be Increasing across the Globe

    Cancer
  • Mesothelioma is a Deadly Cancer and it’s Completely Preventable
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  • Association of Community Cancer Centers and Advisory Board Launch 9th Annual Trends in Cancer Care Survey
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines